Allenaâs lead product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases. Allenaâs second product candidate, ALLN-346, is in preclinical development for patients with hyperuricemia and moderate to severe CKD. Hyperuricemia, or elevated levels of uric acid in the blood, is commonly associated with gout as well as kidney stones and kidney disorders. Source
No articles found.
Patterson Companies Inc. (Nasdaq: PDCO) connects dental and animal health customer...
Patterson Companies Inc. (Nasdaq: PDCO) connect...
Headquartered in Santa Barbara, California, Sientra is a diversified global medica...
Headquartered in Santa Barbara, California, Sie...
G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on th...
G1 Therapeutics, Inc., is a clinical-stage biop...
Turning Point Therapeutics is a clinical-stage precision oncology company with a p...
Turning Point Therapeutics is a clinical-stage ...
Join the National Investor Network and get the latest information with your interests in mind.